Alnylam tumbles, BridgeBio gains after heart drug data

seekingalpha08-31

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) and BridgeBio Pharma (NASDAQ:BBIO) moved in opposite directions on Friday as Wall Street reacted to the latest Phase 3 data for the companies' lead ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2463001760?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412214688/image_1412214688.jpg","is_english":true,"pubTime":"2024-08-31 02:23","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2463001760","market":"sh","top_or_hot":-1,"title":"Alnylam tumbles, BridgeBio gains after heart drug data","media":"seekingalpha","content":"<div>\n<p>Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) and BridgeBio Pharma (NASDAQ:BBIO) moved in opposite directions on Friday as Wall Street reacted to the latest Phase 3 data for the companies' lead ...</p>\n\n<a href=\"https://seekingalpha.com/news/4145618-alnylam-stock-falls-bridgebio-stock-gains-attr-cm-data\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alnylam tumbles, BridgeBio gains after heart drug data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlnylam tumbles, BridgeBio gains after heart drug data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-31 02:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4145618-alnylam-stock-falls-bridgebio-stock-gains-attr-cm-data><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) and BridgeBio Pharma (NASDAQ:BBIO) moved in opposite directions on Friday as Wall Street reacted to the latest Phase 3 data for the companies' lead ...</p>\n\n<a href=\"https://seekingalpha.com/news/4145618-alnylam-stock-falls-bridgebio-stock-gains-attr-cm-data\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://seekingalpha.com/news/4145618-alnylam-stock-falls-bridgebio-stock-gains-attr-cm-data","article_id":"2463001760","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412214688/image_1412214688.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2463001760","pubTimestamp":1725042214,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) and BridgeBio Pharma (NASDAQ:BBIO) moved in opposite directions on Friday as Wall Street reacted to the latest Phase 3 data for the companies' lead asse","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BAYRY":"Bayer A.G.","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4568":"美国抗疫概念","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4550":"红杉资本持仓","SG9999002232.USD":"Allianz Global High Payout USD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","SG9999002224.SGD":"Allianz Global High Payout SGD","ALNY":"阿尔尼拉姆制药公司","LU0058720904.USD":"联博国际健康护理基金A","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BBIO":"BridgeBio Pharma, Inc.","BK4505":"高瓴资本持仓","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4581":"高盛持仓","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4548":"巴美列捷福持仓","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","PFE":"辉瑞","BK4516":"特朗普概念","SG9999001176.USD":"United Global Healthcare Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4592":"伊斯兰概念","LU2308191902.HKD":"BNP PARIBAS ECOSYSTEM RESTORATION \"CLASSIC\" (HKD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4129":"建筑与工程","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","ACM":"Aecom Technology Corporation","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BAYZF":"Bayer A.G.","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"心脏药物数据公布后，Alnylam股价下跌，BridgeBio上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":1,"BAYRY":1,"BAYZF":1,"BBIO":1,"ACM":1,"PFE":0.7},"content_text":"Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) and BridgeBio Pharma (NASDAQ:BBIO) moved in opposite directions on Friday as Wall Street reacted to the latest Phase 3 data for the companies' lead assets, vutrisiran and acoramidis. The drugs targeted at a fatal heart condition known as ATTR amyloidosis with cardiomyopathy (ATTR-CM) were part of two Phase 3 readouts presented at the European Society of Cardiology in London on Friday. Alnylam's (ALNY) presentation on complete data from a Phase 3 trial for vutrisiran gained attention in the premarket, with UBS calling it supportive of a more robust profile for the RNA interference therapy compared to Pfizer's (PFE) rival ATTR-CM therapy tafamidis, marketed as Vyndamax. \"We think the data was supportive of a strong profile for vutrisiran, particularly with a 22% benefit on top of tafamidis in the composite primary endpoint of all-cause mortality (ACM) and CV events,\" UBS wrote. However, Alnylam (ALNY) stock fell, reversing the strong gains it recorded YTD, mainly on the hopes for vutrisiran in ATTR-CM. Leerink Partners noted that with a significant first-line use for vutrisiran in ATTR-CM already priced in Alnylam (ALNY), \"this blue-sky commercial case is a tougher sell given today's data.\" The company expects to begin global regulatory submissions for the drug later this year.  Meanwhile, BridgeBio (BBIO) shares reached a 52-week high after posting Phase 3 data for its ATTR-CM therapy acoramidis, which is currently under FDA review, with a decision due by Nov. 29. The readout from the company's Phase 3 ATTRibute-CM trial and its open-label extension (OLE) demonstrated that switching from tafamidis to acoramidis led to an increase in serum TTR, which is linked to less heart failure risk and better survival. BridgeBio (BBIO) has partnered with Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) to market acoramidis for ATTR-CM in Europe, where the drug is currently under the regulatory review, with a decision anticipated in 2025.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"Business Data","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2463001760"}